Cytokinetics reports positive phase 3 trial results for aficamten

May 5, 2026 7:30 AM

Cytokinetics, Incorporated (NASDAQ: CYTK) announced that its phase 3 clinical trial ACACIA-HCM met both primary endpoints for aficamten in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found